Speech-Language Pathologists in Lynwood, CA Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Ms. Margaret Michelle Damiano-lantz, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11321 Bullis Rd, Lynwood, CA 90262 Phone: 310-886-1600

Ms. Stephanie Rivera Cepeda, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5151 Niland St, Lynwood, CA 90262 Phone: 424-832-4882

Sarah Yabroff, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3630 E Imperial Hwy, Lynwood, CA 90262 Phone: 202-577-6033

Dana Cruse Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3636 E Imperial Hwy Ste C, Lynwood, CA 90262 Phone: 310-294-9596

Cotorro Communication Center, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5151 Niland St, Lynwood, CA 90262 Phone: 424-832-4882

Yevgeniya Pokhylko, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3680 E Imperial Hwy Ste 504, Lynwood, CA 90262 Phone: 310-807-7545

News Archive

Patient monitoring technology helps mental health trust to reduce falls and save time

Coventry and Warwickshire Partnership NHS Trust saw falls at night drop by a third on two wards that introduced the Oxehealth Digital Care Assistant technology, a clinical study has shown.

Patient survival higher among white children than minorities post liver transplant

Novel research reveals racial and socioeconomic disparities among pediatric liver transplant patients. Findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, indicate that graft and patient survival was higher in white children than minorities.

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

Multi-detector row computed tomography predicts malignancy of IPMNs

A clinical research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses the role of multi-detector row computed tomography (MDCT) in predicting malignancy of IPMNs preoperatively. The research team led by Prof. Wang DB from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine recruited a total of 20 patients with pathologically-confirmed IPMNs in their study. Axial MDCT images combined with CT angiography (CTA) and multiplanar volume or curved reformations (MPVR or CR) were preoperatively acquired.

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

Read more Medical News

› Verified 7 days ago